Enorama Pharma
0.45 SEK
-9.84 %
Less than 1K followers
ERMA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Enorama Pharma
EV/S
Median 2019-2022
P/B
Median 2019-2024
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Share price (SEK) | 33.40 | 27.30 | 18.35 | 3.01 | 2.56 | 3.36 |
| Shares | 6.5 | 7.2 | 9.3 | 11.3 | 49.6 | 60.5 |
| Market cap | 217.7 | 195.5 | 171.0 | 34.1 | 126.9 | 203.2 |
| Enterprise value | 232.5 | 219.1 | 179.4 | 36.3 | - | - |
| EV/S | 30.5 | 102.1 | 16.3 | 5.3 | - | - |
| EV/EBITDA | neg. | neg. | neg. | neg. | - | - |
| EV/EBIT | neg. | neg. | neg. | neg. | - | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 30.33 | 109.99 | 8.01 | 1.02 | 6.49 | 26.05 |
| P/S | 28.6 | 91.1 | 15.5 | 5.0 | 93.3 | 12.9 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 16.9 % | 4.3 % | 41.9 % | 66.1 % | 56.8 % | 49.1 % |
| Gearing ratio | 408.9 % | 1,599.3 % | 96.3 % | 18.7 % | 23.0 % | - |